Simeprevir & sofosbuvir demonstrates good early cure rate with or without ribavirin
The advent of direct-acting antiviral agents has brought about a new era of treatment for chronic hepatitis C virus (HCV) infection. Several new drug candidates have been shown to increase effectiveness when added to pegylated interferon and ribavirin, but many people with hepatitis C and their clinicians are awaiting regimens that omit interferon and its difficult side-effects.
Eric Lawitz from Alamo Medical Research in Texas presented interim findings from an open-label, exploratory phase 2a study looking at all-oral regimens containing simeprevir (formerly TMC435), a NS3/4A protease inhibitor being jointly developed by Janssen and Medivir, plus Gilead Sciences' NS5B polymerase inhibitor sofosbuvir (formerly GS-7977), with or without ribavirin.
View abstract 155LB on the conference website.
A webcast of the session in which this research was presented, Advances in ARV and Anti-Hepatitis C Virus Therapy, is available on the conference website.